ICD variantCongenital viral hepatitis is a specific ICD-10 coded subtype of Hepatitis. The clinical content below covers Hepatitis in general.
NeonatologysevereICD-10 · P35.3
Congenital viral hepatitis.Care & specialists in Brazil
In Brazil, congenital viral hepatitis is managed by neonatologists. Hepatitis is inflammation of the liver, most commonly caused by hepatitis viruses A, B, C, D, and E, with smaller contributions from autoimmune disease, alcohol, drugs, metabolic dysfunction, and toxins. WHO estimates 354 million people live with chronic hepatitis B or C globally and 1.1 million die each year from cirrhosis and liver cancer caused by these viruses.
Scleral icterus (yellowing of the white of the eye) — a classic clinical sign of hepatitis. · Credit: James Heilman, MD / Wikimedia Commons · CC BY-SA 3.0
Hepatitis (ICD-10: B15-B19 for viral; K70-K77 for non-viral) means inflammation of the liver, defined biochemically by elevation of hepatocellular enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and histologically by inflammatory infiltrate and hepatocyte injury. The most common causes are viral: hepatitis A virus (HAV), spread by the fecal-oral route, causes acute self-limited disease; hepatitis B virus (HBV), spread by blood, sexual contact, and mother-to-child transmission, causes both acute and chronic disease; hepatitis C virus (HCV), spread predominantly by blood, causes chronic disease in 75% of those infected; hepatitis D virus (HDV) infects only those with concurrent HBV and accelerates progression; and hepatitis E virus (HEV), spread by contaminated water and pork, causes acute disease with severe outcomes in pregnant women. Non-viral hepatitis includes autoimmune hepatitis (mediated by T-cell attack on hepatocytes), alcoholic hepatitis (from sustained heavy alcohol intake), drug-induced liver injury (from over-the-counter, prescription, and herbal agents), and metabolic dysfunction-associated steatotic liver disease (MASLD) with steatohepatitis. Hepatitis is described as acute if liver inflammation lasts less than 6 months and chronic if it persists beyond that threshold.
key facts
Prevalence
354 million people living with chronic HBV (296M) or HCV (58M) globally (WHO 2022)
Demographics
Hepatitis B: highest prevalence in Western Pacific and Africa; hepatitis C: highest in Eastern Mediterranean and Europe; hepatitis A: common where sanitation is limited
Avg. age
Acute hepatitis A peaks in children in endemic regions and unvaccinated travelers; chronic HBV and HCV typically diagnosed in adults aged 30-60
Global cases
§ 02
How you might notice it
The key symptoms of Congenital viral hepatitis are: Profound fatigue lasting weeks, often the dominant complaint and present across all hepatitis types., Right upper quadrant abdominal discomfort, ache, or fullness from hepatic capsular distension., Nausea, reduced appetite, and a particular aversion to fatty food, often with mild weight loss over weeks., Jaundice — yellowing of the skin and the sclera of the eyes — appearing when serum bilirubin exceeds 3 mg/dL, present in 30-50% of symptomatic acute viral hepatitis., Dark tea-colored urine and pale, clay-colored stools, reflecting conjugated bilirubin in urine and reduced biliary excretion to the gut., Itch (pruritus) across the body, especially in cholestatic forms of hepatitis, sometimes preceding visible jaundice., Low-grade fever and joint pain in the prodromal phase of acute viral hepatitis, sometimes mistaken for influenza..
01Profound fatigue lasting weeks, often the dominant complaint and present across all hepatitis types.
02Right upper quadrant abdominal discomfort, ache, or fullness from hepatic capsular distension.
03Nausea, reduced appetite, and a particular aversion to fatty food, often with mild weight loss over weeks.
04Jaundice — yellowing of the skin and the sclera of the eyes — appearing when serum bilirubin exceeds 3 mg/dL, present in 30-50% of symptomatic acute viral hepatitis.
05
§ 03
How it’s diagnosed
diagnosis
Diagnosis of hepatitis follows a structured pathway: confirm hepatocellular injury, identify the cause, assess severity, and characterize chronicity. Initial blood tests show elevated ALT and AST with variable bilirubin, albumin, and INR. Acute viral hepatitis typically produces ALT in the thousands; alcoholic hepatitis shows AST greater than ALT with a ratio above 2; autoimmune hepatitis shows moderate transaminase elevation with hypergammaglobulinemia. Serologic testing for each virus is essential: HAV IgM for acute hepatitis A; HBsAg, anti-HBc IgM, and anti-HBs for HBV (with HBeAg, HBV DNA, and anti-HDV in chronic disease); anti-HCV antibody followed by HCV RNA for HCV; anti-HEV IgM and HEV RNA in suspected cases. The 2020 CDC and AASLD-IDSA guidelines recommend at least one-time HBV and HCV screening for all adults, plus risk-based testing. Autoimmune hepatitis is identified by autoantibodies (ANA, ASMA, anti-LKM1, anti-LC1), elevated serum IgG, and confirmed by liver biopsy showing interface hepatitis. Acute alcoholic hepatitis is diagnosed by history (over 40 g/day for women or 60 g/day for men over several months), serum bilirubin above 3 mg/dL, and AST greater than ALT with AST under 500 IU/L. Imaging with ultrasound, transient elastography (FibroScan), or magnetic resonance elastography quantifies fibrosis non-invasively. Liver biopsy remains the gold standard for autoimmune hepatitis confirmation and for staging when non-invasive assessment is discordant. In chronic disease, twice-yearly ultrasound with alpha-fetoprotein measurement screens for hepatocellular carcinoma in cirrhotic patients and selected non-cirrhotic chronic HBV carriers.
Key tests
01
Liver function tests (ALT, AST, bilirubin, albumin, INR)Confirm hepatocellular injury, assess severity, and characterize the pattern (hepatitic vs cholestatic). Elevations in the thousands suggest acute viral hepatitis or ischemic injury; AST/ALT ratio above 2 suggests alcoholic disease.
02
Hepatitis A IgM antibodyConfirms acute hepatitis A infection. Positive within 5-10 days of symptom onset and remains positive for 3-6 months.
✓Prednisolone induction with azathioprine maintenance (autoimmune hepatitis)
✓Prednisolone 40 mg daily for 28 days (severe alcoholic hepatitis)
surgical options
Liver transplantation1-year graft survival above 90% and 5-year survival above 75% in adult elective transplantation in high-volume centers (UNOS data).
Transjugular intrahepatic portosystemic shunt (TIPS)Variceal rebleeding rates fall to under 20% with TIPS versus over 50% with endoscopic therapy alone; risk of hepatic encephalopathy in 20-30%.
Hepatocellular carcinoma resection and ablation5-year survival 60-70% for resectable solitary HCC; comparable for small tumors treated by ablation.
§ 05
Causes & risk factors
known causes
Hepatitis A virus infection
Acquired by ingestion of food or water contaminated with fecal material. Outbreaks occur with contaminated produce, shellfish, or food handlers in non-vaccinated populations. The virus replicates in hepatocytes, causing T-cell-mediated injury and acute hepatitis without chronic carriage.
Hepatitis B virus infection
Transmitted by exposure to infected blood, semen, or vaginal fluids — through unprotected sex, shared needles, unsafe medical injections, mother-to-child transmission at birth, and rarely transfusion. HBV integrates and persists in hepatocytes, with chronicity rate depending heavily on age at exposure.
Hepatitis C virus infection
Transmitted predominantly by blood-to-blood contact — injection drug use, transfusion before 1992 routine screening, unsafe medical and tattoo procedures, occasional vertical and sexual transmission. Chronic infection follows in 75% of adults; without treatment, leads to cirrhosis in 15-30% over 20-30 years.
Hepatitis D, E and other viral hepatitides
Hepatitis D requires HBV surface antigen and infects only HBV-positive individuals, accelerating disease. Hepatitis E spreads by contaminated water (genotypes 1, 2) and zoonotically by pork or game meat (genotypes 3, 4). Other viruses (CMV, EBV, HSV) can cause hepatitis in immunocompromised patients.
Autoimmune attack on hepatocytes
T-cell-mediated destruction of hepatocytes driven by loss of self-tolerance and association with HLA-DR3 and HLA-DR4 in white populations. Characterized by autoantibodies, elevated IgG, and interface hepatitis on biopsy. Female predominance and bimodal age distribution (peri-adolescent and middle age).
Alcohol-related liver injury
Sustained alcohol intake (over 40 g/day in women, 60 g/day in men for years) produces steatosis, oxidative stress, and immune-mediated injury that can manifest as alcoholic hepatitis — sometimes severe and life-threatening, particularly when combined with HCV, MASLD, or HBV.
§ 06
Living with it
01Receive the hepatitis B vaccination series at birth and complete the schedule by 6-18 months; universal adult vaccination is now recommended for all adults 19-59 (CDC 2022)
02Receive the hepatitis A vaccine series before travel to endemic regions and as part of routine childhood vaccination
03Use safe injection practices: never share needles, syringes, or drug preparation equipment; use sterile equipment for tattoos and piercings
04Practice safer sex with condoms, particularly in serodiscordant relationships and for hepatitis B prevention
05Drink safe (boiled or bottled) water and avoid raw shellfish in regions with hepatitis A or E transmission
recommended foods
•Balanced Mediterranean-style diet with vegetables, fruits, whole grains, fish, and olive oil
•Adequate protein (1.0-1.2 g/kg per day; up to 1.5 g/kg in cirrhotic patients with sarcopenia) to prevent muscle wasting
•Coffee — 3-4 cups daily, associated with lower fibrosis progression and HCC risk in observational studies
§ 07
When to seek help
why see a neonatology
Patients with confirmed chronic viral hepatitis (HBV, HCV, HDV), autoimmune hepatitis, acute severe alcoholic hepatitis, decompensated liver disease, or hepatocellular carcinoma should be managed by a hepatologist or infectious disease specialist with hepatitis experience. Primary care can manage uncomplicated acute hepatitis A and E and routine post-cure HCV follow-up, but treatment initiation and staging belong with the specialist. Liver transplant evaluation is mandatory for decompensated cirrhosis and acute liver failure with adverse prognostic indicators.
01Cirrhosis with portal hypertension, ascites, variceal bleeding, and hepatic encephalopathy — develops in 15-40% of untreated chronic HBV and HCV over 30 years
02Hepatocellular carcinoma — rising risk once cirrhosis is established; requires 6-monthly ultrasound surveillance with or without alpha-fetoprotein
03Acute liver failure with coagulopathy and altered mental status — most common in severe acute HBV, drug-induced injury, and hepatitis E in pregnancy
04Renal dysfunction (hepatorenal syndrome) in decompensated cirrhosis
05Extrahepatic manifestations: cryoglobulinemic vasculitis and lymphoma in HCV; polyarteritis nodosa and membranous nephropathy in HBV
Hepatitis A (HAV)Single-stranded RNA picornavirus transmitted by the fecal-oral route. Acute, self-limited illness lasting 4-12 weeks. Does not cause chronic infection. Vaccine-preventable. Approximately 1.5 million symptomatic cases per year globally; case-fatality 0.1-0.3% rising with age and underlying liver disease.
Hepatitis B (HBV)Partially double-stranded DNA hepadnavirus transmitted by blood, sexual contact, and mother-to-child. Acute infection in adults clears in over 90%; perinatally acquired infection becomes chronic in 90%. Chronic HBV affects 296 million people globally. Vaccine-preventable; chronic infection treatable but rarely curable.
Hepatitis C (HCV)Single-stranded RNA flavivirus transmitted predominantly by blood. Becomes chronic in 75% of infected adults. Affects approximately 58 million people globally. Curable in over 95% with 8-12 weeks of direct-acting antivirals — the only chronic viral hepatitis with a true cure.
Hepatitis D (HDV)Defective RNA virus requiring HBV surface antigen to replicate. Coinfects 12-72 million HBV-positive individuals worldwide. Accelerates progression of chronic HBV to cirrhosis and hepatocellular carcinoma. Limited treatment options, with bulevirtide newly approved in Europe.
Hepatitis E (HEV)Single-stranded RNA hepevirus transmitted by contaminated water (genotypes 1 and 2) and zoonotically by undercooked pork or game meat (genotypes 3 and 4). Acute self-limited disease in most; severe in pregnant women with up to 30% case-fatality in third trimester; chronic infection in immunosuppressed patients.
Autoimmune hepatitisChronic immune-mediated liver inflammation with autoantibodies (ANA, ASMA, anti-LKM1), elevated IgG, and characteristic interface hepatitis on biopsy. Responds to corticosteroids and azathioprine in over 80% of patients. Lifetime risk roughly 1 in 6,000.
Living with Congenital viral hepatitis
Timeline
Acute hepatitis A symptoms resolve over 4-8 weeks with full biochemical recovery by 6 months in most cases. Acute hepatitis B in adults resolves over 8-16 weeks. Chronic HCV cured with direct-acting antivirals shows liver enzyme normalization within weeks of starting therapy and SVR12 confirms cure 12 weeks after treatment ends. Chronic HBV on suppressive therapy shows viral suppression within 6-12 months and fibrosis improvement over 1-5 years. Autoimmune hepatitis remission is reached in 6-12 months with corticosteroid and azathioprine therapy. Severe alcoholic hepatitis recovery depends on alcohol abstinence and response to corticosteroid therapy assessed at day 7 with the Lille score.
Lifestyle
01Abstain from alcohol completely if you have any chronic hepatitis — alcohol accelerates fibrosis progression at any intake level
02Maintain a healthy body weight; weight loss of 7-10% can reverse metabolic-associated steatohepatitis in clinical trials
03Avoid herbal supplements and high-dose acetaminophen (more than 2 g daily) in chronic liver disease
04Receive hepatitis A and B vaccination if not previously vaccinated and serologically susceptible
05Take all prescribed antiviral medications without missed doses — adherence is critical for HBV viral suppression
06Disclose hepatitis status to all healthcare providers to enable safe care and infection control
Daily management
Complementary approaches
Coffee consumption (3-4 cups daily)Observational data consistently associate coffee intake with lower fibrosis progression and hepatocellular carcinoma incidence in chronic hepatitis C and other liver diseases. Mechanism unclear but may relate to caffeine, polyphenols, and anti-inflammatory effects. Adjunctive only — not a substitute for antiviral therapy.
Choosing a doctor
Look for a hepatologist or infectious disease specialist with experience in viral hepatitis treatment, access to fibrosis assessment (FibroScan, MRI elastography), and a multidisciplinary team including hepatobiliary surgery and interventional radiology. For HCV treatment, expertise with current direct-acting antiviral regimens and access to insurance prior authorization support are essential. For autoimmune hepatitis, prefer centers with hepatology and rheumatology collaboration.
Patient support resources
American Liver Foundation →US patient organization with educational resources, support groups, and information on all forms of hepatitis.
WHO Hepatitis Resources →World Health Organization global hepatitis program with country-level data, prevention guidance, and strategy documents.
CDC Viral Hepatitis →US CDC patient and clinician information on hepatitis A, B, C, D, and E with current screening and treatment recommendations.
§ 08
Frequently asked
What are the main types of hepatitis?▾▴
The main types are viral hepatitis A, B, C, D, and E, plus non-viral causes including autoimmune hepatitis, alcoholic hepatitis, drug-induced hepatitis, and metabolic dysfunction-associated steatohepatitis (MASH). Each type has distinct transmission, course, treatment, and prevention strategies. Hepatitis A and E are typically acute; B, C, and D can become chronic.
How is hepatitis spread?▾▴
Hepatitis A and E spread through contaminated food and water. Hepatitis B and C spread through blood and body fluids — injection drug use, unprotected sex, unsafe medical injections, and mother-to-child transmission. Hepatitis D only infects people already infected with hepatitis B. Non-viral hepatitis is not contagious.
What are the symptoms of hepatitis?▾▴
Common symptoms include fatigue, nausea, loss of appetite, abdominal discomfort, dark urine, pale stools, and yellowing of the skin and eyes (jaundice). Many people with chronic hepatitis B or C are asymptomatic for years until advanced liver damage develops. Routine screening is recommended because of this silent course.
Is hepatitis curable?▾▴
Hepatitis C is curable in over 95% of patients with 8-12 weeks of direct-acting antiviral therapy. Hepatitis A and E are self-limiting and recover fully. Hepatitis B is rarely cured but can be suppressed indefinitely with oral antivirals. Hepatitis D has limited options but bulevirtide is newly approved in Europe. Autoimmune hepatitis is controlled long-term but typically not cured.
What is the difference between hepatitis A, B, and C?▾▴
Hepatitis A is spread by fecal-oral route, is acute and self-limited, and is vaccine-preventable. Hepatitis B is spread by blood and sex, can be acute or chronic, and is vaccine-preventable but rarely cured. Hepatitis C is spread mostly by blood, becomes chronic in 75% of adults, and is curable in over 95% with direct-acting antivirals — though no vaccine exists.
Is there a vaccine for hepatitis?▾▴
Yes, for hepatitis A and B. Both are part of routine childhood vaccination in most countries and recommended for all adults. There is no vaccine for hepatitis C, D (other than via HBV vaccination), or E (a vaccine exists in China but is not widely available). Hepatitis B vaccination protects against hepatitis D since HDV requires HBV to replicate.
How is hepatitis diagnosed?▾▴
Diagnosis starts with blood tests showing elevated liver enzymes (ALT, AST) and bilirubin. Specific testing follows: hepatitis A IgM, hepatitis B surface antigen and antibodies, hepatitis C antibody and RNA, autoantibodies for autoimmune hepatitis, and history for alcoholic and drug-induced hepatitis. Imaging and sometimes liver biopsy stage the severity.
Can hepatitis be treated at home?▾▴
Mild acute hepatitis A or E without dehydration or signs of liver failure can often be managed at home with rest, fluids, antiemetics, avoidance of alcohol and hepatotoxic drugs, and close clinician follow-up. Chronic hepatitis B and C require specialist evaluation and treatment. Any signs of confusion, vomiting blood, or progressive jaundice require immediate hospital care.
How long does hepatitis last?▾▴
Acute hepatitis A lasts 4-8 weeks with full recovery in over 95% of cases. Acute hepatitis B in adults usually resolves over 8-16 weeks; only 5-10% become chronic. Hepatitis C becomes chronic in 75% of infected adults and is lifelong without treatment. With current direct-acting antivirals, HCV is cured in 8-12 weeks in over 95% of treated patients.
Can chronic hepatitis cause liver cancer?▾▴
Yes. Chronic hepatitis B and C are leading global causes of hepatocellular carcinoma. Risk rises substantially once cirrhosis develops but also occurs in non-cirrhotic HBV carriers. Six-monthly ultrasound surveillance with or without alpha-fetoprotein is recommended in patients with cirrhosis or high-risk HBV. Antiviral therapy reduces but does not eliminate cancer risk.
Is alcoholic hepatitis the same as cirrhosis?▾▴
No. Alcoholic hepatitis is acute liver inflammation from sustained heavy drinking that can occur with or without underlying cirrhosis. Cirrhosis is the end-stage scarring of the liver after years of chronic injury — sometimes precipitated by repeated alcoholic hepatitis. Severe alcoholic hepatitis carries 28-day mortality of 20-40%; abstinence is the single most effective intervention.
Can hepatitis be passed from mother to baby?▾▴
Yes. Hepatitis B is the most common: without intervention, 70-90% of infants born to HBeAg-positive mothers develop chronic hepatitis B. Universal birth-dose HBV vaccine and HBIG for high-risk infants prevent over 95% of transmissions. Hepatitis C transmission to infants is approximately 5-6%, higher in HIV co-infection. Hepatitis E in pregnancy can be severe.
Do all chronic hepatitis B patients need treatment?▾▴
Not all chronic hepatitis B patients require immediate treatment. Treatment is recommended for those with active hepatitis (elevated ALT plus high HBV DNA), evidence of fibrosis, cirrhosis, or extrahepatic manifestations. Patients in the inactive carrier phase are monitored every 6-12 months. EASL 2017 and AASLD 2018 guidelines define eligibility criteria.
How do direct-acting antivirals cure hepatitis C?▾▴
Direct-acting antivirals (DAAs) block specific steps in HCV replication — NS3/4A protease, NS5A, and NS5B polymerase. Pangenotypic combinations like sofosbuvir-velpatasvir and glecaprevir-pibrentasvir achieve sustained virologic response in 95-99% across all genotypes, including in cirrhotic patients. Treatment duration is typically 8-12 weeks.
Is hepatitis sexually transmitted?▾▴
Hepatitis B is efficiently transmitted by sexual contact and is considered a sexually transmitted infection. Hepatitis C transmission by sex is uncommon between monogamous heterosexual partners but more common in men who have sex with men, particularly in HIV co-infection. Hepatitis A can occasionally spread by oral-anal sexual practices. Condom use and vaccination reduce risk.
Can hepatitis cause autoimmune disease?▾▴
Hepatitis C is associated with cryoglobulinemic vasculitis, glomerulonephritis, and B-cell lymphoma. Chronic hepatitis B is associated with polyarteritis nodosa and membranous nephropathy. Autoimmune hepatitis itself is an autoimmune disease causing liver inflammation. The relationship between infection, autoimmunity, and hepatitis is complex and frequently bidirectional.
What is hepatitis E?▾▴
Hepatitis E is acute viral hepatitis caused by hepatitis E virus, spread by contaminated water (genotypes 1 and 2 in Asia and Africa) and undercooked pork or game meat (genotypes 3 and 4 in Europe and North America). Most cases recover fully but mortality reaches 30% in third-trimester pregnant women. Chronic infection occurs in immunosuppressed patients.
Should I get screened for hepatitis B and C?▾▴
Yes. The CDC and US Preventive Services Task Force now recommend universal one-time screening for hepatitis B and C in all adults 18 and older, in addition to risk-based and pregnancy screening. Most chronic hepatitis B and C is asymptomatic for years, and early diagnosis allows effective treatment that prevents cirrhosis and liver cancer.
What should I avoid if I have hepatitis?▾▴
Avoid alcohol completely, limit acetaminophen to under 2 g daily, and avoid herbal supplements and unprescribed medications that can cause additional liver injury. Avoid raw shellfish, which can transmit hepatitis A and cause severe infection in cirrhotic patients. Disclose your hepatitis status to all healthcare providers so they can prescribe safely.
Can children get hepatitis?▾▴
Yes. Hepatitis A is common in children where sanitation is limited and is often mild or asymptomatic. Hepatitis B can be acquired at birth from infected mothers and becomes chronic in 90% of perinatally exposed infants. Universal HBV birth-dose vaccination prevents this. Hepatitis C in children is uncommon but occurs through vertical transmission.
1.1 million hepatitis-related deaths per year (WHO 2022); hepatocellular carcinoma is the major cause of mortality
Specialist
Neonatology
ICD-10
P35.3
Dark tea-colored urine and pale, clay-colored stools, reflecting conjugated bilirubin in urine and reduced biliary excretion to the gut.
06Itch (pruritus) across the body, especially in cholestatic forms of hepatitis, sometimes preceding visible jaundice.
07Low-grade fever and joint pain in the prodromal phase of acute viral hepatitis, sometimes mistaken for influenza.
08Most chronic hepatitis is asymptomatic for years — fatigue, vague abdominal symptoms, and abnormal liver tests on routine bloodwork are often the only clues until cirrhosis develops.
early warning signs
•Persistently elevated ALT or AST on routine blood work without an obvious explanation
•Unexplained fatigue lasting more than 4 weeks in someone with risk factors (injection drug use, multiple sexual partners, transfusion before 1992, healthcare exposure, birth in an endemic region)
•Acholic (pale) stools and dark urine appearing together
•New or worsening yellowing of the eyes or skin, especially with recent travel to a region with unsafe water
•Vague right upper quadrant discomfort in adults with alcohol use disorder or metabolic syndrome
● emergency signs
•Confusion, drowsiness, agitation, or asterixis (flapping tremor) — possible hepatic encephalopathy requiring urgent hospital evaluation
•Vomiting blood or passing black tarry stools — possible variceal bleeding requiring emergency endoscopy
•Rapidly progressive jaundice with INR above 1.5 in acute hepatitis — possible acute liver failure requiring transplant center referral
•Severe abdominal swelling (ascites) with fever and abdominal pain — possible spontaneous bacterial peritonitis requiring urgent paracentesis and antibiotics
•Pregnant woman with acute hepatitis in the third trimester — particularly hepatitis E, with high maternal mortality requiring urgent specialist care
03
Hepatitis B serologic panel (HBsAg, anti-HBs, anti-HBc, HBV DNA)Identifies acute or chronic HBV infection, prior exposure, vaccine response, and viral replication level. HBsAg positive for over 6 months defines chronic infection.
04
Hepatitis C antibody with reflex HCV RNAAnti-HCV antibody indicates current or prior infection; HCV RNA distinguishes current viremia from cleared infection. RNA quantitation guides treatment monitoring.
05
Autoimmune hepatitis serology (ANA, ASMA, anti-LKM1, anti-LC1, anti-SLA, IgG)Identifies type 1 (ANA, ASMA) and type 2 (anti-LKM1, anti-LC1) autoimmune hepatitis. Elevated serum IgG above 1.1 times the upper limit of normal supports the diagnosis.
06
Liver ultrasound and DopplerAssesses liver echogenicity, size, surface nodularity, and portal vein flow. Detects features of cirrhosis, focal lesions, and biliary obstruction.
07
Transient elastography (FibroScan)Non-invasive measurement of liver stiffness as a surrogate for fibrosis stage. Replaces biopsy in many patients for staging chronic hepatitis B, C, and MASH.
08
Liver biopsy with histopathologyDefinitive assessment of inflammation grade and fibrosis stage; essential for diagnosing autoimmune hepatitis and distinguishing overlap syndromes.
Outlook
Prognosis depends heavily on cause, chronicity, and timing of intervention. Acute hepatitis A and E in immunocompetent adults resolve fully in over 95-99% of cases; acute hepatitis B in adults clears in over 90%. Untreated chronic hepatitis B progresses to cirrhosis in 15-40% over 30 years, with HCC incidence rising further once cirrhosis is established. Antiviral suppression with tenofovir or entecavir reduces cirrhosis and HCC by 50-70% and improves overall survival. Untreated chronic hepatitis C progresses to cirrhosis in 15-30% over 20-30 years. Cure with direct-acting antivirals reverses fibrosis in many patients and reduces HCC incidence by 70%, though residual risk persists in cirrhotic patients who achieved cure. Autoimmune hepatitis has an excellent prognosis with treatment — 10-year survival above 90% — but requires long-term maintenance therapy. Severe alcoholic hepatitis carries 28-day mortality of 20-40% depending on severity score and response to steroid therapy; sustained alcohol abstinence reduces long-term mortality substantially. Metabolic-associated steatohepatitis with advanced fibrosis is now the most rapidly rising indication for liver transplant. Across all causes, early detection through risk-based screening and prompt initiation of treatment are the strongest predictors of favorable long-term outcome.
Drug- and toxin-induced liver injury
Acetaminophen overdose, antibiotics (amoxicillin-clavulanate, isoniazid), antiepileptics, statins, methotrexate, herbal preparations (kava, green tea extract, comfrey), and dietary supplements are leading causes of drug-induced liver injury. Acute presentation can resemble viral hepatitis.
Hepatic insulin resistance and lipotoxicity drive accumulation of free fatty acids and inflammation in hepatocytes. Now the most rapidly rising indication for liver transplant in the US and projected to overtake HCV as the leading cause of liver-related mortality.
risk factors
Injection drug usemodifiable
Most important modifiable risk factor for hepatitis C transmission, accounting for over 60% of new HCV cases in high-income countries. Also raises HBV and HIV co-infection risk substantially.
Birth in an HBV-endemic regionnon-modifiable
Adults born in regions with HBV surface antigen prevalence above 2% (Asia, Africa, Pacific Islands, Eastern Europe) have prevalence rates of 5-15%. CDC recommends universal screening of all adults born in these regions.
Multiple sexual partners or unprotected sexmodifiable
Raises HBV transmission risk; lesser effect on HCV transmission except with traumatic anal intercourse or HIV co-infection. Condom use and vaccination of partners reduce risk.
Heavy alcohol usemodifiable
Daily intake over 30 g for men and 20 g for women raises risk of alcoholic hepatitis and accelerates fibrosis in any underlying liver disease. Abstinence is the single most effective intervention.
Obesity, type 2 diabetes, and metabolic syndromemodifiable
Drive metabolic dysfunction-associated steatohepatitis (MASH). Weight loss of 7-10% can reverse steatohepatitis in clinical trials.
Maternal HBV infection at birthnon-modifiable
Without intervention, 70-90% of infants born to HBeAg-positive mothers develop chronic HBV. Universal birth-dose HBV vaccination and HBIG for high-risk infants reduce transmission by over 95%.
Healthcare exposure to blood and body fluidsoccupational
Needlestick injuries and mucocutaneous exposures raise HBV, HCV, and HIV risk. Universal precautions, vaccination, and post-exposure prophylaxis substantially reduce occupational risk.
Travel or residence in regions with unsafe water and foodenvironmental
Hepatitis A and E are acquired through contaminated water and food. Travelers should be vaccinated for HAV; hepatitis E avoidance relies on water and food safety practices.
•
Whole-grain complex carbohydrates and high-fiber foods to support glycemic control
•Vitamin D-rich foods and supplementation to maintain 25-OH-D above 30 ng/mL
foods to avoid
•Alcohol in any amount with chronic hepatitis
•Acetaminophen above 2 g daily, particularly with cirrhosis or chronic hepatitis
•Herbal supplements (kava, green tea extract, comfrey, chaparral) which can cause drug-induced liver injury
•Raw or undercooked shellfish, which can transmit hepatitis A and aggravate cirrhosis through vibriosis risk
•Excessive sodium (over 2 g per day) in cirrhotic patients with ascites
06
Vertical (mother-to-child) transmission of HBV and HCV, particularly in mothers with high viral load
Compare →
Alcoholic and metabolic-associated hepatitis
Alcoholic hepatitis follows sustained heavy drinking and can be fatal in severe presentations. Metabolic dysfunction-associated steatohepatitis (MASH) — formerly NASH — affects approximately 5% of adults globally and is now a leading indication for liver transplant in the US.
01Take chronic HBV antiviral medication at the same time daily — adherence directly determines viral suppression and progression risk
02Attend scheduled monitoring: liver function tests every 3-6 months and HCC surveillance ultrasound every 6 months in high-risk patients
03Avoid alcohol, acetaminophen above 2 g daily, and unprescribed herbal supplements
04Carry a medical card noting your chronic hepatitis diagnosis and current medications
05Inform all healthcare providers and dentists of your hepatitis status to enable safe care
06Vaccinate household contacts and sexual partners against hepatitis A and B
Exercise
At least 150 minutes of moderate aerobic exercise weekly plus twice-weekly resistance training. Exercise improves insulin sensitivity, reduces hepatic fat, and counteracts sarcopenia of advanced liver disease. In cirrhotic patients, avoid heavy resistance training that produces a Valsalva maneuver and worsens portal hypertension. Adjust intensity downward during active acute hepatitis until biochemical recovery.
